Referanser
Alle artikler fra referansene i listen under kan bestilles fra Medisinsk informasjonstjeneste hos AstraZeneca AS. Klikk på referansen for å se abstract fra studien.
- Godkjent preparatomtale for Symbicort®
- Godkjent preparatomtale for Oxis®
- Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
Eur Respir J 2003; 22:s912-919
- Szafranski W et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Eur Respir J 2003; 21:74-81
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy For the Diagnosis, Management, and Prevention of COPD
NHLBI/WHO Workshop Report. http://www.goldcopd.com
- Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation.
Am Rev Respir Dis 1992; 145:1321-1327.
- Löfdahl C-G, Andreasson E, Svensson K and Ericsson A. Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs.
Eur Resp J 2003; 22, Suppl 45; 50s.
- Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice.
Respir Med 1999; 93:173-9.
- Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease.
Thorax 1997; 52: 67-71.
- Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax 2002; 57:847-52).
- Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 1998; 157:1418-22.
- Veileder til diagnose, behandling og forebygging av kronisk obstruktiv lungesykdom (KOLS) Norsk utgave til bruk for leger og annet helse-personell November 2002 ved den norske Lægeforenings Strategigruppe for KOLS, Amund Gulsvik et al.
Vedlegg til Tidsskrift for Norske Legeforning. ISBN 82 - 8070010 - 2 nr 28 2002
- Soriano JB, Kiri VA, Pride NB, Vestbo J.Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients.
Am J Respir Med 2003;2:67–74
- Fabbri L, Beghe B, Caramori G, Papi A, Saetta M Similarities and discrepancies between exacerbation of asthma and chronic obstructive pulmonary disease.
Thorax 1998;53:803-808 (September)
- Fjellanger R, Brøgger J, Eagan T Gulsvik A. Mortality after hospitalization for obstructive lung disease in a Norwegian hospital district.
Eur Respir J 2002; 20 (Suppl 38):202s.
- Haughney J, Vogelmeier C, Kessler R, Partridge MR, Stahl E. Important attributes of COPD exacerbations: a conjoint analysis.
European Respiratory Journal 2004;24(Suppl 48):514s, Abs P3207.
- Vestbo J. What is an exacerbation of COPD?
European Respiratory Review 2004;13(88):6-13.
- Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD; Ambulatory Care Quality Improvement Project Investigators. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases.
Chest 2002 Aug;122(2):429-36.
- Nanna Eriksen, Ejvind Frausing Hansen, Erik P. Munch, Finn Vejlø Rasmussen & Jørgen Vestbo Kronisk obstruktiv lungesygdom Indlæggelse, forløb og prognose.
Ugeskrift for Læger · 8. september 2003, nr. 37
- Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.
Chest 2003 Aug;124(2):459-67.
- Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau J. Mortality after hospitalization for COPD.
Chest 2002 May;121(5):1441-8.
- Kiri V A, Bettoncelli G,Testi R, Viegi G Inhaled corticosteroides are more effective in COPD patients when used with LABA than with SABA.
Respiratory Medicine Vol 99, Issue 9, Sept 2005, p 1115- 1124.
- Katsura H & Kida K. A Comparision of Bone Minaral Density in Elderly Female Patients With COPD and Bronchial Astma.
Chest 2002;122:1949-1955.
- McEvoy CE, Ensrud KE, Bender E et al Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 1998; 157: 704- 709.
- Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group.
Arch Intern Med 1999; 159:1215-1220.
- Iqbal F, Michaelson J, Thaler, et al. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment; body mass index, and gonadal function.
Chest 1999; 116: 1616-1624.
- Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences.
Eur Respir J 1994;7: 1056-61.
- Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung Health study.
JAMA 1994;272: 1497- 505.
- Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Pulmonary Disease.
N Engl J Med 1999; 340: 1948-53.
- Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS, Pride NB et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler.
Eur Respir J 2002; 19: 1058-63.
Ikke logget inn
Quick Links
For helsepersonell
